Mirati Therapeutics CFO Stelzer to depart Sept 8; Aaron Ondrey named interim CFO

Mirati Therapeutics, Inc.

CFO Laurie Stelzer resigns effective Sept 8, 2023 to pursue opportunity at another biotech; will consult through Oct 2023.
Aaron Ondrey (SVP FP&A since July 2022) appointed interim CFO; base salary increased to $450k.
Ondrey receives retention award: $300k cash plus $300k in RSUs vesting 90 days after permanent CFO hired.
Mirati recently completed an upsized public offering, extending cash runway through upcoming milestones.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Laurie Stelzer

Chief Financial Officer

Mirati Therapeutics, Inc.

Effective: 2023-09-08
Successor: Aaron Ondrey
Filed: August 23, 2023, 7:59 PM ET

On August 17, 2023, Laurie Stelzer notified Mirati Therapeutics, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Financial Officer and principal financial and accounting officer, effective as of September 8, 2023

Appointed (interim)

Aaron Ondrey

Interim Chief Financial Officer

Mirati Therapeutics, Inc.

Effective: 2023-09-08
Filed: August 23, 2023, 7:59 PM ET

On August 21, 2023, the Board of Directors of the Company (the “Board”) appointed Aaron Ondrey, the Company’s Senior Vice President, Financial Planning and Analysis, as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of the Separation Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Laurie Stelzer resigned as Chief Financial Officer at Mirati Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On August 17, 2023, Laurie Stelzer notified Mirati Therapeutics, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Financial Officer and principal financial and accounting officer, effective as of September 8, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Aaron Ondrey was appointed as Interim Chief Financial Officer at Mirati Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On August 21, 2023, the Board of Directors of the Company (the “Board”) appointed Aaron Ondrey, the Company’s Senior Vice President, Financial Planning and Analysis, as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of the Separation Date.

View on SEC.gov

Source: SEC EDGAR

accession 0001628280-23-030373

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.